PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33768546-13	2021	The haematocrit (HCT), postoperative time (POD) and CYP3A5*3 genotypes had a significant influence on TAC clearance when combined with WZC.	Tacrolimus	102-105	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	52-58	
33768546-15	2021	For patients carrying the CYP3A5*3/*3 allele and with 30% HCT, the required TAC dose to achieve target trough concentrations of 10-15 ng/ml was 4 mg twice daily (q12h).	Tacrolimus	76-79	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	26-32	
33768546-16	2021	For patients with the CYP3A5*3/*3 allele, the required dose was 3 mg TAC q12h when combined with WZC, and for patients with the CYP3A5*1/*1 or *1/*3 allele, the required dose was 4 mg of TAC q12h when co-administered with WZC.	Tacrolimus	69-72	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	22-28	
33768546-16	2021	For patients with the CYP3A5*3/*3 allele, the required dose was 3 mg TAC q12h when combined with WZC, and for patients with the CYP3A5*1/*1 or *1/*3 allele, the required dose was 4 mg of TAC q12h when co-administered with WZC.	Tacrolimus	187-190	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	128-134	
33768546-17	2021	WHAT IS NEW AND CONCLUSION: Wuzhi Capsule co-administration and CYP3A5 variants affect the PK of TAC Dosing guidelines are made based on the PPK model to allow individualized administration of TAC, especially when co-administered with WZC.	Tacrolimus	97-100	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	64-70	
33768546-17	2021	WHAT IS NEW AND CONCLUSION: Wuzhi Capsule co-administration and CYP3A5 variants affect the PK of TAC Dosing guidelines are made based on the PPK model to allow individualized administration of TAC, especially when co-administered with WZC.	Tacrolimus	193-196	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	64-70